SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Increase (Decrease) in Prepaid Expense
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Increase (Decrease) in Prepaid Expense of -$121.87 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-03-31
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in prepaid expense for the quarter ending 2025-06-30 was -$72.55K, a 834.56% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in prepaid expense for the quarter ending 2025-03-31 was $156.02K, a 928.53% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in prepaid expense for the quarter ending 2024-12-31 was $187.73K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in prepaid expense for the quarter ending 2024-09-30 was -$36.48K, a 140.02% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in prepaid expense for fiscal 2025 was -$121.87K, a 169.12% decline from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in prepaid expense for fiscal 2024 was $176.30K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in prepaid expense for fiscal 2023 was -$46.67K, a 129.87% decline from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in prepaid expense for fiscal 2022 was $156.28K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$121.87K 10-K · filed 2026-03-31 | |||
| 2025-06-30 | -$72.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $83.47K 10-Q · filed 2025-08-13 | $271.20K derived: sum of 3 quarters · filed 2026-03-31 | $234.73K derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-03-31 | $156.02K 10-Q · filed 2025-05-08 | $343.75K derived: sum of 2 quarters · filed 2026-03-31 | $307.27K derived: sum of 3 quarters · filed 2026-03-31 | $317.15K derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-12-31 | $187.73K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $151.25K derived: sum of 2 quarters · filed 2026-03-31 | $161.13K derived: sum of 3 quarters · filed 2026-03-31 | $176.30K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$36.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$26.60K derived: sum of 2 quarters · filed 2025-08-13 | -$11.43K 10-Q · filed 2024-11-13 | -$67.06K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-06-30 | $9.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $25.05K 10-Q · filed 2025-08-13 | -$30.59K derived: sum of 3 quarters · filed 2025-08-13 | $60.57K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $15.17K 10-Q · filed 2025-05-08 | -$40.46K derived: sum of 2 quarters · filed 2025-05-08 | $50.69K derived: sum of 3 quarters · filed 2025-05-08 | -$74.19K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$55.63K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $35.52K derived: sum of 2 quarters · filed 2025-02-26 | -$89.36K derived: sum of 3 quarters · filed 2025-02-26 | -$46.67K 10-K · filed 2025-02-26 |
| 2023-09-30 | $91.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$33.73K derived: sum of 2 quarters · filed 2024-11-13 | $8.96K 10-Q · filed 2024-11-13 | $6.96K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$124.89K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-09-04 | -$82.20K 10-Q · filed 2024-09-04 | -$84.19K derived: sum of 3 quarters · filed 2024-09-04 | $65.43K derived: sum of 4 quarters · filed 2024-09-04 |
| 2023-03-31 | $42.69K 10-Q/A · filed 2024-09-04 | $40.69K derived: sum of 2 quarters · filed 2024-09-04 | $190.32K derived: sum of 3 quarters · filed 2024-09-04 | $183.22K derived: sum of 4 quarters · filed 2024-09-04 |
| 2022-12-31 | -$1.99K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | $147.63K derived: sum of 2 quarters · filed 2024-09-04 | $140.53K derived: sum of 3 quarters · filed 2024-09-04 | $156.28K 10-K/A · filed 2024-09-04 |
| 2022-09-30 | $149.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $142.53K derived: sum of 2 quarters · filed 2023-11-13 | $158.28K 10-Q · filed 2023-11-13 | $155.84K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$7.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $8.65K 10-Q · filed 2023-08-14 | $6.22K derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $15.75K 10-Q · filed 2023-05-25 | $13.31K derived: sum of 2 quarters · filed 2023-05-25 | ||
| 2021-12-31 | -$2.43K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$7.71K 10-K · filed 2023-03-15 | ||
| 2021-09-30 | -$5.28K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |